Latest Articles

Publication Date
Identification of hub genes and pathways in Uterine corpus endometrial carcinoma (UCEC): A comprehensive in silico study.

Uterine corpus endometrial carcinoma (UCEC), derived from the endometrium, is the most common type of endometrial malignasis. This gynecological malignancy is very common all over the world, especially in developed …

Published: Nov. 1, 2024, midnight
Undifferentiated Endometrial Carcinoma Occurred During Perimenopausal Hormone Therapy: A Case Report and Literature Review - Frontiers

Undifferentiated Endometrial Carcinoma Occurred During Perimenopausal Hormone Therapy: A Case Report and Literature Review Frontiers

Published: Oct. 18, 2024, 10:58 a.m.
Retrospective, Observational, Pilot Study to Assess the Safety and Efficacy of Goel’s Technique of Laparoscopic Hysterectomy in Endometrial Carcinoma - Cureus

Retrospective, Observational, Pilot Study to Assess the Safety and Efficacy of Goel’s Technique of Laparoscopic Hysterectomy in Endometrial Carcinoma Cureus

Published: Oct. 15, 2024, 12:12 p.m.
Incarcerated Incisional Hernia: An Unusual Presentation of Metastatic Endometrial Carcinoma - Cureus

Incarcerated Incisional Hernia: An Unusual Presentation of Metastatic Endometrial Carcinoma Cureus

Published: Oct. 15, 2024, 5:32 a.m.
Melanoma Cell Adhesion Molecule (CD 146) in Endometrial Physiology and Disorder.

The human endometrium, the innermost lining of the uterus, is the anatomic prerequisite for pregnancy. It is the only dynamic tissue that undergoes more than 400 cycles of regeneration throughout …

Published: Oct. 15, 2024, midnight
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress

FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress

Published: June 24, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay

FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay

Published: June 21, 2024, 7 a.m.
Androgen-responsive FOXP4 is a target for endometrial carcinoma | Communications Biology - Nature.com

Androgen-responsive FOXP4 is a target for endometrial carcinoma | Communications Biology Nature.com

Published: June 18, 2024, 7 a.m.
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile - Wiley Online Library

The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile Wiley Online Library

Published: June 18, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology

FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology

Published: June 18, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!